Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — American Thoracic Society – Respiratory Innovation Summit 2025
9 slides from Kymera Therapeutics's conference presentation, May 2025
Slide 1: Revolutionizing Immunology: Oral Medicines with Biologics-like Activity
May 2025 Revolutionizing Immunology: Oral Medicines with Biologics-like Activity Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics American Thoracic Society – Respiratory Innovation Summit
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about our strategy, business
Slide 3: Kymera is a Leader in Targeted Protein Degradation: Oral Drugs with Biologics-Like Efficacy
Kymera is a Leader in Targeted Protein Degradation (TPD): Oral Drugs with Biologics-Like Efficacy Science-driven Clinical Stage Organization with Industry-leading Oral Immunology Pipeline 1 Catching the Target Protein 2 Presenting the Target Protein • Novel technology: Leverages natural protein recy
Slide 4: Small Molecule Oral Degraders Can Transform Immunology
Small Molecule Oral Degraders Can Transform Immunology Potentially Superior Profile to Injectable Biologics and Traditional Small Molecule Inhibitors Biologics can have several limitations, making orals preferred by most patients • Expensive, challenging to prescribe/reimburse • Immunogenicity 75% •
Slide 5: Building the Best-in-Industry Oral Immunology Pipeline
Building the Best-in-Industry Oral Immunology Pipeline • Undrugged or inadequately drugged targets Unique Target • Strong genetic/clinical pathway validation Selection Strategy • Clear path to early clinical differentiation • Multiple indications with significant unmet medical need Potential Upcomin
Slide 6: STAT6 Degrader: Opportunity for Dupilumab-Like Activity in a Pill
STAT6 Degrader: Opportunity for Dupilumab-Like Activity in a Pill STAT6 Highly Validated but Undrugged Target TRANSCRIPTION FACTOR • IL-4/IL-13 pathway highly validated by dupilumab (IL-4Rα mAb): approved in 7 indications IL-4/13 Pathway • STAT6 is the specific transcription factor for IL-4/IL-13 si
Slide 7: KT-621 Preclinical Profile: First Investigational Oral STAT6 Degrader to Advance into the Clinic
KT-621 Preclinical Profile: First Investigational Oral STAT6 Degrader to Advance into the Clinic Highly Selective STAT6 Degrader with No Impact on Other STAT Family Members STAT6 Degradation in Immune Cells Exquisite Picomolar Selectivity Potency IL-13 Induced Periostin Release in Human STAT6 Degrad
Slide 8: KT-621 Blocks Th2 Inflammation In Vivo Equal to or Better than Dupilumab in HDM Asthma Model
KT-621 Blocks Th2 Inflammation In Vivo Equal to or Better than an IL-4Rα Saturating Dose of Dupilumab in the Intranasal HDM Asthma Model Serum IgE and Lung Cytokines Inflammatory Lung Infiltrate Lung Goblet Cell Metaplasia Total Serum IgE BAL IL-5 BAL CD4+ T Cell BAL CD8+ T Cell BAL TARC (CCL17) BAL
Slide 9: KT-621 Development Path to Key Proof-of-Concept Inflection Points
KT-621 Development Path to Key Proof-of-Concept Inflection Points Trial Objectives Phase 1 Healthy Volunteers Safety and tolerability of robust STAT6 degradation in blood (Completed – Data in June 2025) and skin measured over 14 days / Impact on Th2 biomarkers Phase 1b Atopic Dermatitis Patients Imp
Kymera Therapeutics — American Thoracic Society – Respiratory Innovation Summit 2025 on 6ix